Prosecution Insights
Last updated: April 19, 2026

Acerta Pharma B V

3 pending office actions

Portfolio Summary

3
Total Pending OAs
2
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18488169 BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment HOWELL, THEODORE R 1628 Non-Final OA Oct 17, 2023
18487254 Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide WILLIS, DOUGLAS M 1624 Final Rejection Oct 16, 2023
18001740 ACALABRUTINIB MALEATE DOSAGE FORMS HAVLIN, ROBERT H 1626 Final Rejection Dec 14, 2022

Managing Acerta Pharma B V's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month